ETAO International Co., Ltd.
ETAO
NASDAQ Capital Market1.91
USD
-0.89
- -
CIK
0001939696
ISIN
KYG313631072
Return %
Stock
S&P500
1Y
-78.78
24.99
3Y
-99.02
70.19
5Y
-99.02
77.45
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Wensheng Liu
- Full Time Employees
- 3,600
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 1460 Broadway New York City NY United States of America 10036
- IPO Date
- Jun 24, 2021
- CIK
- 0001939696
- Website
- etao.world
- Similar Companies
- Business
- ETAO International Co., Ltd. (ETAO) operates as a digital healthcare company that develops an integrated ecosystem encompassing online telemedicine, artificial intelligence diagnostics, big data evaluation, online health insurance, pharmacy services, biotechnology solutions, offline hospitals, and specialty clinics including infertility treatment, orthopedic surgery, plastic surgery, primary care, reproductive health, oncology, rehabilitation, digital pathology, precision diagnostics, and AI dental imaging. The company delivers medical consultations, chronic disease management such as digital diabetes care, and end-to-end patient services through proprietary applications connecting physicians, pharmacies, and medical vendors across regions, primarily targeting Chinese patients via technology-powered telemedicine and OMO (online-merge-offline) models. Founded in 2020 and headquartered at 1460 Broadway, 14th Floor, New York, NY, ETAO maintains operational presence in North America, China, Canada, Latin America, and Australia, with approximately 3,600 employees, 12 hospitals, 30 clinics, over 5 million online registered users, and a network of more than 3,000 global medical experts. Recent strategic acquisitions include HiPatho for digital pathology, DiaCarta for precision diagnostics, and 6D Dental for AI dental imaging, alongside over 12 additional deals enhancing global capabilities; the company reports unaudited 2024 consolidated revenue exceeding $150 million and projects pro forma 2025 revenue surpassing $660 million with full integration, while targeting Nasdaq relisting by Q4 2025 following legal planning in Q1 2025 and operational consolidation through Q3. ETAO trades on OTC Markets under ticker ETAO/ETAOF, with Chairman, Founder, and CEO Wensheng Liu leading strategic expansions in AI-driven medical technology, dental, and precision diagnostics sectors supported by PIPE funding, equity partners, and investments in scalable U.S. healthcare assets.
ETAO International Co., Ltd. Announces 1 for 20 Reverse Share Split, Increase of Authorized Shares and Alteration to Its Share Capital
Why Is Etao International (ETAO) Stock Up 149% Today?
ETAO Announces receiving a staff determination - Delinquency letter from Nasdaq
Why Is Etao International (ETAO) Stock Down 37% Today?
ETAO International Co. Ltd. Received Nasdaq Delisting Determination
4 Top Penny Stocks To Buy For Under $5